Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 1% – What’s Next?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s stock price traded down 1% on Monday . The stock traded as low as $1.8503 and last traded at $1.91. 17,664 shares were traded during trading, an increase of 84% from the average daily volume of 9,605 shares. The stock had previously closed at $1.93.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Alaunos Therapeutics Stock Performance

The company has a market cap of $46.64 million, a price-to-earnings ratio of -1.00 and a beta of -1.00. The company’s fifty day moving average is $2.06 and its two-hundred day moving average is $2.55.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP purchased a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned approximately 0.54% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is owned by institutional investors and hedge funds.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.